Bruker Reports Q1 Results Ahead of Expectations, Reaffirms Full-Year Guidance

summarizeSummary

Bruker Corporation announced first-quarter 2026 financial results, exceeding expectations despite organic revenue decline, and reconfirmed its full-year 2026 revenue and non-GAAP EPS guidance.

check_boxKey Events

• Q1 2026 Financial Performance

  Reported Q1 2026 revenues of $823.4 million (up 2.7% year-over-year, down 4.4% organically) and non-GAAP diluted EPS of $0.31, with management noting performance was ahead of expectations.

• Full-Year 2026 Guidance Reaffirmed

  Reconfirmed previous FY2026 guidance for revenues of $3.57 to $3.60 billion (4-5% year-over-year growth) and non-GAAP EPS of $2.10 to $2.15 (15-17% year-over-year growth), signaling confidence despite Q1 organic decline.

• Strong Bookings Trend

  Bruker Scientific Instruments (BSI) segment bookings grew organically at a high-single digit percentage, with a book-to-bill ratio above 1.0x for the third consecutive quarter, indicating future revenue growth.

auto_awesomeAnalysis

Bruker Corporation announced first-quarter 2026 financial results, reporting revenues of $823.4 million, a 2.7% year-over-year increase, though organic revenue declined by 4.4%. GAAP diluted EPS was $0.02, while non-GAAP diluted EPS reached $0.31. Despite the organic revenue dip, management stated that financial performance came in ahead of expectations. Crucially, the company reconfirmed its full-year 2026 guidance, projecting revenues of $3.57 to $3.60 billion (4-5% year-over-year growth) and non-GAAP EPS of $2.10 to $2.15 (15-17% year-over-year growth). This reconfirmation, following a challenging 2025 with a net loss and impairment charges, provides a stabilizing signal. The Bruker Scientific Instruments (BSI) segment also reported high-single digit organic bookings growth and a book-to-bill ratio above 1.0x for the third consecutive quarter, indicating future revenue strength and a potential return to organic growth in Q2.